NS5A inhibitors belong to a class of modern direct-acting antivirals that are used in therapies against HCV. These antivirals target specific regions of viral non-structural proteins NS3/4A, NS5A and NS5B, and are generally used in combinations, to increase its efficacy. Although the rates of sustained virological response increased to approximately 95%, with the development of these new drugs, new problems are arising due to the detection of resistance associated substitutions (RAS) in the amino acid chain of the target proteins. NS5A is one of the most variable genes in HCV and, therefore, the detection of baseline RAS in this protein, in individuals chronically infected by HCV and from a vulnerable population, is of particular interest due to the possible implications for the future treatment. This Bioproject contains partial sequences generated by amplification of the NS4B-NS5A region.
Less...